GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (OTCPK:RTNXF) » Definitions » EV-to-EBIT

Renalytix (Renalytix) EV-to-EBIT : -1.30 (As of May. 10, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Renalytix EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Renalytix's Enterprise Value is $50.53 Mil. Renalytix's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-38.73 Mil. Therefore, Renalytix's EV-to-EBIT for today is -1.30.

The historical rank and industry rank for Renalytix's EV-to-EBIT or its related term are showing as below:

RTNXF' s EV-to-EBIT Range Over the Past 10 Years
Min: -47.77   Med: -2.28   Max: -0.35
Current: -1.3

During the past 6 years, the highest EV-to-EBIT of Renalytix was -0.35. The lowest was -47.77. And the median was -2.28.

RTNXF's EV-to-EBIT is ranked worse than
100% of 428 companies
in the Healthcare Providers & Services industry
Industry Median: 18.68 vs RTNXF: -1.30

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Renalytix's Enterprise Value for the quarter that ended in Dec. 2023 was $17.05 Mil. Renalytix's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-38.73 Mil. Renalytix's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -227.12%.


Renalytix EV-to-EBIT Historical Data

The historical data trend for Renalytix's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renalytix EV-to-EBIT Chart

Renalytix Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBIT
Get a 7-Day Free Trial -3.77 -36.88 -28.49 -1.27 -2.86

Renalytix Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.12 -1.64 -2.86 -1.71 -0.54

Competitive Comparison of Renalytix's EV-to-EBIT

For the Health Information Services subindustry, Renalytix's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Renalytix's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Renalytix's EV-to-EBIT falls into.



Renalytix EV-to-EBIT Calculation

Renalytix's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=50.526/-38.726
=-1.30

Renalytix's current Enterprise Value is $50.53 Mil.
Renalytix's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-38.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Renalytix  (OTCPK:RTNXF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Renalytix's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-38.726/17.05124382
=-227.12 %

Renalytix's Enterprise Value for the quarter that ended in Dec. 2023 was $17.05 Mil.
Renalytix's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-38.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Renalytix EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Renalytix's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Renalytix (Renalytix) Business Description

Traded in Other Exchanges
Address
5-7 Cranwood Street, Finsgate, London, GBR, EC1V 9EE
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Renalytix (Renalytix) Headlines

From GuruFocus

New Published Real-World Evidence Shows KidneyIntelX� Utility

By sperokesalga sperokesalga 04-19-2023

Renalytix to Present at Stifel Healthcare Conference

By Value_Insider Value_Insider 11-03-2022